Abstract
This review provides an overview of the currently used nuclear medicine imaging modalities and ongoing developments in the imaging of neuroendocrine tumors (NETs). Most NETs overexpress the somatostatin receptor mainly sst2. Somatostatin receptor scintigraphy with 111In-DTPA-0octreotide has proven its role in the diagnosis and staging of gastroenteropancreatic NETs. The use of 68Ga-labeled analogs of octreotide for PET imaging, with of different radiolabelled somatostatin analogues with higher affinity and different affinity profiles to the somatostatin receptor subtypes such as DOTATOC, DOTANOC, and DOTA-TATE, are in clinical application in nuclear medicine. The development PET tracers for NET imaging include Fluorodihydroxyphenylalanine (18FDOPA) and fluorodeoxyglucose (18FDG). 18FDOPA-PET appears to be a major tool for the management of carcinoid tumors with excellent diagnostic performances. The role of 18FFDG PET-CT in the prognosis of neuroendocrine tumors should be evaluated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
